Forecast
The analysts' average price target is €93.77 (+82.29%). The median is €94.78 (+84.25%).
| Buy |
Â
18 |
| Hold |
Â
6 |
| Sell |
Â
2 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
PTC Therapeutics raises forecast – Wells Fargo sees 74% upside potential from Sephience
PTC Therapeutics reports robust sales driven by the drug Sephience and raises its full-year forecast. Wells Fargo reaffirms its buy rating and sets a price target of $112, implying roughly 74% upside. Management says Sephience’s market penetration is proceeding as planned. » More on finanzen.net
PTC Therapeutics: SEPHIENCE drives revenue momentum, cash-flow breakeven targeted for 2026
At the Cantor Healthcare Conference PTC Therapeutics reported a strong SEPHIENCE launch in PKU with over 2,000 therapy-start applications in the U.S. and a global revenue potential of more than $2 billion. The company shows over $2 billion in cash and expects cash-flow breakeven in 2026. Phase‑2 data for votoplam in Huntington’s chorea demonstrated a 52% slowing of disease progression at the higher dose; a Phase‑3 study is already ongoing. PTC is also acquiring ST-920 for Fabry disease (upfront payment $111 million), which is in the BLA stage and could have peak sales potential of more than $750 million. » More on de.investing.com
PTC Therapeutics counts on SUFIANCE as growth driver and targets cash-flow breakeven in 2026
At the Wells Fargo conference PTC Therapeutics outlined its strategy: shifting away from older products toward a broader rare-disease portfolio. SUFIANCE (Pegvaliase) is driving growth, has reached all 103 US centers of excellence and is expected to offer more than $2 billion in revenue potential. Management reports more than $2 billion in cash, disciplined cost reductions and expects cash-flow breakeven in 2026. Meanwhile PTC is expanding its pipeline (including Votoplam, MSH3, Vatiquinon, NLRP3) and is acquiring the gene therapy ST-920 for Fabry disease ($100–110 million) for further diversification. » More on de.investing.com
PTC Therapeutics acquires gene therapy ST-920 for Fabry disease in bankruptcy auction
PTC Therapeutics purchased ST-920 from Sangamo Therapeutics in a bankruptcy auction. The deal includes an upfront payment of $111 million and up to $100 million in regulatory approval milestone payments. PTC plans to complete the BLA filing for accelerated approval in the U.S. by Q4 2026 and then pursue international approvals using its existing infrastructure. Closing remains subject to contract documentation, bankruptcy court approval and antitrust review, and is expected in late Q3/early Q4 2026. » More on de.investing.com
PTC Therapeutics: Sephience launch brings record sales and more than $2 billion in potential
PTC Therapeutics achieves record sales from the launch of Sephience and sees peak revenue potential of more than $2 billion. The company focuses on targeted interventions in RNA biology to treat diseases such as DMD and PKU. In addition, positive long-term data for Votoplam against Huntington triggered a $50 million milestone payment from Novartis. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsIn 2013, PTC Therapeutics has already paid €0.0663 in dividends. The last payout was in June 2013.
Financials
In the last quarter, PTC Therapeutics had revenue of €315.89m and net profit of -€45.64m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 315.89m | 75.68% |
| Gross profit | 295m | 264.15% |
| Net profit | -45.64m | 436.92% |
| EBITDA | 19.07m | 8.47% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.3bn |
Number of shares | 83.54m |
52-week high/low | €82.81 - €51.20 |
| Dividends | No |
Beta | 0.51 |
P/E ratio | -43.07 |
PEG ratio | 0.61 |
P/B ratio | -24.63 |
P/S ratio | 4.08 |
Company profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Name | PTC Therapeutics |
| CEO | Matthew Klein |
| Headquarters | Warren,
nj USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 20/06/2013 |
| Employees | 991 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | PTCT |
Frankfurt | BH3.F |
DĂĽsseldorf | BH3.DU |
SIX | P91.SW |
MĂĽnchen | BH3.MU |